XPEV and 9868:HK Related Headlines
Go Back- XPeng (H-Shares) (9868:HK) (XPEV) PT Lowered to HK$77 at CLSA
- Macquarie Reiterates Outperform Rating on XPeng (H-Shares) (9868:HK) (XPEV)
- XPeng (H-Shares) (9868:HK) (XPEV) PT Lowered to HK$135 at JPMorgan
- XPeng (H-Shares) (9868:HK) (XPEV) PT Lowered to HK$100 at Macquarie
- Morgan Stanley Reiterates Overweight Rating on XPeng (H-Shares) (9868:HK) (XPEV)
- XPeng (H-Shares) (9868:HK) (XPEV) PT Lowered to HK$110.60 at Citi
- XPeng (H-Shares) (9868:HK) (XPEV) PT Raised to HK$195 at JPMorgan
- XPeng (H-Shares) (9868:HK) (XPEV) PT Raised to HK$123 at Macquarie
- Morgan Stanley Reiterates Overweight Rating on XPeng (H-Shares) (9868:HK) (XPEV), added to GEM and APxJ Focus Lists
- CLSA Reiterates Outperform (2) Rating on XPeng (H-Shares) (9868:HK) (XPEV)
- XPeng (H-Shares) (9868:HK) (XPEV) PT Raised to HK$114.80 at Citi
- XPeng (H-Shares) (9868:HK) (XPEV) PT Lowered to HK$98 at Macquarie
- XPeng (H-Shares) (9868:HK) (XPEV) PT Raised to HK$99 at Macquarie
- XPeng (H-Shares) (9868:HK) (XPEV) PT Raised to HK$82 at Bernstein SocGen Group
- XPeng (H-Shares) (9868:HK) (XPEV) PT Lowered to HK$100 at JPMorgan
- Goldman Sachs Upgrades XPeng (H-Shares) (9868:HK) (XPEV) to Buy
- XPeng (H-Shares) (9868:HK) (XPEV) PT Raised to HK$108 at Morgan Stanley

